At a glance
ClinicalIndex Comparison RecordN/ACompleted· 191 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
In Brief
An observational study for Psoriasis. Completed, enrolled 191 participants.
Detailed Summary
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years. Reasons for interrupting or permanently discontinuing Humira therapy and reasons for restarting Humira therapy will be noted. An evaluation will be performed of the effect of the disease on quality of life and work productivity.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsVeeda Clinical Research
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJul 2010
Primary CompletionMar 2015
TodayJul 2026
First PostedJul 27, 2010
Enrollment StartMay 1, 2010
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 15.9 years ago